US equities finished higher overnight after a choppy session following the release of FOMC meeting minutes, which showed caution among policymakers, fuelling bets that rates would stay steady. The Dow edged higher, up 66 points (+0.19%). Up 143 at best. Down 127 at worst. The S&P 500 rose for a fourth straight session, up 0.43%,…
US equities finished higher overnight after a choppy session following the release of FOMC meeting minutes, which showed caution among policymakers, fuelling bets that rates would stay steady. The Dow edged higher, up 66 points (+0.19%). Up 143 at best. Down 127 at worst. The S&P 500 rose for a fourth straight session, up 0.43%, and the NASDAQ rose 0.71%
SMALL CAP PORTFOLIO 3.00pm Updates Nothing done today. Selected lithium stocks recovering from oversold levels. PMT, CXO, AZS to name a few. Market impetus running out as US CPI approaches. Volumes in small caps remain low. CSL a major drag as US Med tech under pressure on new kidney trial results using the ‘miracle’ weight…
Buy signals on the All Ordinaries, ASX 200, S&P 500 and Nasdaq are now 4 days old. There are now MACD buy signals as well. Telstra (TLS) weekly buy signal. Again. Not often traded by Australians – but there’s a buy signal on SQ2. Qantas (QAN), anyone?. Very early short-term buy signal after dropping from 670c to 490c over the Qatar debacle (not their fault).
Our market up again – we are four days into this rally with the US CPI number to worry about tonight
The Doves are still flapping – we are four days into this market rally
CBA had its AGM yesterday – the share price dropped 0.31% (hardly changed), with one broker saying there was "No new news". A fairly quiet affair. Just a lot of motherhood comments about assisting the cost of living pressures, holding a strong balance sheet, and remaining well placed heading into a lower growth environment. There…
CSL fell 6.3% today continuing its nasty downtrend, as the GLP-1 (obesity drugs) juggernaut continues to smash through the healthcare sector. It has already destroyed ResMed (RMD) and yesterday their five year study into the GLP-1 efficacy in treating chronic kidney disease and Type 2 diabetes was halted early because the results were so good. It is…
ASX 200 limped to a 3-point gain to 7091 (+0.04%) ahead of US CPI. Six sessions in a row. Just. CSL was the biggest drag on the index as positive drug trials in the US marred the outlook for medical companies. The stock fell 6.3%, RMD down 5.3% on the same effect. Banks once again…
ASX 200 limped to a 3-point gain to 7091 (0.04%) ahead of US CPI. Six sessions in a row. Just. CSL was the biggest drag on the index as positive drug trials in US marred outlook for medical companies. The stock fell 6,3%, RMD down 5.3% on same effect.
